Three novel Zn(II) complexes [ZnCl2(H2LtBu)], [ZnCl2(Me2LtBu)] and [Zn2Cl4(H2LCatBiPyPh)2] (where H2LtBu is 2,6-bis(5-tert-butyl-1H-pyrazol-3-yl)pyridine, Me2LtBu is 2,6-bis(5-tert-butyl-1-methyl-1H-pyrazol-3-yl)pyridine and H2LCatBiPyrPh is 1,2-bis((5-phenyl-1H-pyrazol-3-yl)methoxy)benzene) were synthesized and characterized using various spectroscopic techniques, including UV-vis, IR, 1D (1H and 13C) and 2D (1H–1H COSY) NMR. The structures of complexes [ZnCl2(H2LtBu)] and [Zn2Cl4(H2LCatBiPyPh)2] were elucidated through X-ray crystallography. The interactions of the complexes with CT-DNA and human serum albumin (HSA) were investigated using UV-vis spectroscopy and fluorescence emission titration. All examined complexes exhibited quenching constant, Ksv, values in the order of 104 with CT-DNA. Constant values followed the trend [ZnCl2(Me2LtBu)] < [Zn2Cl4(H2LCatBiPyPh)2] < [ZnCl2(H2LtBu)]. The results indicated a moderate interaction between the complexes and HSA. In terms of cytotoxic activity, the zinc(II) complexes significantly decreased the viability of colon (HCT-116) and pancreatic (MIA PaCa-2) cancer cell lines, where the effect on pancreatic cells after 72 h is especially emphasized. The most pronounced occurrence of apoptosis, as the dominant type of complex-induced cell death, was associated with complex [ZnCl2(H2LtBu)], while necrosis was observed at lower percentages in all investigated treatments. All complexes demonstrated downregulation of the tumor suppressor gene TP53 (homo sapiens tumor protein p53). Treatment with [ZnCl2(H2LtBu)] resulted in downregulation of TP53, CASP3 (Caspase 3) and IGF1R (insulin-like growth factor 1), potentially impairing the effective apoptotic process and reducing cell proliferation.
20 February 2024 in Applied Organometallic Chemistry
The development of anticancer agents has long been a focus of pharmaceutical research, and coordination chemistry plays a crucial role in this field. While platinum-based drugs, such as cisplatin, have been successful, they suffer from limitations like resistance and toxicity. In this context, heterometallic complexes—coordination compounds containing more than one type of metal ion—have emerged as promising candidates for novel antitumor therapies. These compounds offer unique opportunities for fine-tuning biological activity through synergistic metal interactions, structural diversity, and tailored physicochemical properties. This mini-review provides a detailed overview of the potential of heterometallic complexes in treating cancerous diseases, focusing on their ability to combine different metal ions for enhanced efficacy, overcome limitations associated with traditional therapies, and improve selective targeting of tumor cells. By leveraging the complementary properties of multiple metal centers, heterometallic complexes offer new avenues for cancer treatment, potentially providing more effective, less toxic, and more targeted therapeutic options.